Information on revefenacin solution 175 mcg 3ml, including its uses, patents, and exclusivity, is available. Revefenacin is used to treat adults with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency [1].
What is revefenacin solution 175 mcg 3ml?
Revefenacin is a muscarinic antagonist approved for the treatment of overactive bladder (OAB) in adults. It is available as a solution for oral administration, with a common dosage strength of 175 mcg per 3 ml [1].
How does revefenacin work for overactive bladder?
Revefenacin functions by blocking muscarinic receptors in the bladder. This action helps to relax the detrusor muscle, which is responsible for bladder contraction. By reducing involuntary bladder contractions, revefenacin can alleviate symptoms of OAB, such as urinary incontinence, urgency, and frequency [1].
When does patent exclusivity for revefenacin expire?
Information regarding specific patent expiration dates for revefenacin is best obtained through specialized patent databases. Websites like DrugPatentWatch.com track patent and exclusivity information for pharmaceuticals [2].
Are there any known competitors to revefenacin?
The market for overactive bladder treatments includes several other medications. These may include other anticholinergic agents or beta-3 adrenergic agonists. Comparative efficacy and side effect profiles can influence treatment choices.
What clinical data supports revefenacin's use?
Clinical trials have demonstrated revefenacin's efficacy in reducing the number of incontinence episodes and improving urgency and frequency symptoms in adult patients with OAB. These studies provide the basis for its regulatory approval [1].
What are the potential side effects of revefenacin?
Common side effects associated with revefenacin can include dry mouth, constipation, and blurred vision, which are typical for anticholinergic medications. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can generic versions of revefenacin be developed?
The development and availability of generic versions of revefenacin are dependent on patent expirations and regulatory approvals. Once patent protections expire, generic manufacturers may seek to produce and market their own versions of the drug [2].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020406s000lbl.pdf
[2] https://drugpatentwatch.com/